Dianthus Therapeutics Inc (NASDAQ:DNTH)’s traded shares stood at 0.5 million during the last session, with the company’s beta value hitting 1.84. At the close of trading, the stock’s price was $28.00, to imply an increase of 1.97% or $0.54 in intraday trading. The DNTH share’s 52-week high remains $33.77, putting it -20.61% down since that peak but still an impressive 76.5% since price per share fell to its 52-week low of $6.58. The company has a valuation of $822.36M, with an average of 0.3 million shares in intraday trading volume over the past 10 days and average of 195.67K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Dianthus Therapeutics Inc (DNTH), translating to a mean rating of 1.20. Of 6 analyst(s) looking at the stock, 0 analyst(s) give DNTH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 6 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Dianthus Therapeutics Inc (NASDAQ:DNTH) trade information
After registering a 1.97% upside in the last session, Dianthus Therapeutics Inc (DNTH) has traded red over the past five days. The 5-day price performance for the stock is 2.79%, and 0.07% over 30 days. With these gigs, the year-to-date price performance is 169.23%. Short interest in Dianthus Therapeutics Inc (NASDAQ:DNTH) saw shorts transact 4.33 million shares and set a 31.65 days time to cover.
The extremes give us $51 and $51 for target low and target high price respectively. As such, DNTH has been trading -82.14% off suggested target high and -82.14% from its likely low.
Dianthus Therapeutics Inc (DNTH) estimates and forecasts
Looking at statistics comparing Dianthus Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Dianthus Therapeutics Inc (DNTH) shares are 11.60% up over the last 6 months, with its year-to-date growth rate higher than industry average at 72.54% against 17.60%.
DNTH Dividends
Dianthus Therapeutics Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Dianthus Therapeutics Inc (NASDAQ:DNTH)’s Major holders
Dianthus Therapeutics Inc insiders hold 8.83% of total outstanding shares, with institutional holders owning 101.90% of the shares at 111.77% float percentage. In total, 101.90% institutions holds shares in the company.
